NEW YORK, NY / ACCESSWIRE / November 19, 2018 / U.S. equities finished mostly in the green on Friday as investors digested comments from President Donald Trump, expressing confidence in resolving the current trade dispute between the U.S. and China. The Dow Jones Industrial Average was up 0.49 percent to close at 25,413.22, while the S&P 500 Index increased 0.22 percent to close at 2,736.27. The Nasdaq Composite Index finished 0.15 percent lower at 7,247.87.
According to Michael Arone, chief investment strategist with State Street Global Advisors, “Usually the upcoming holiday season is a great time for the markets, earnings have been strong, and we can still expect to see the lingering effects of tax cuts in the next couple of quarters.”
MERInitiates Coverage on:
Amarin's stock moved 2.43% higher Friday, to close the day at $18.15. The stock recorded a trading volume of 12,784,829 shares, which was below its three months average volume of 17,301,632 shares. In the last year, Amarin's shares have traded in a range of 2.35 - 23.34. The share price has gained 672.34% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $19.84 is above its 200-day moving average of $7.61. Shares of Amarin have fallen roughly 9.75 percent in the past month and are up 352.62 percent year-to-date.
AccessMER's Amarin Corporation plc Research Report at:
On Friday, shares of Seattle Genetics recorded a trading volume of 3,318,179 shares, which was above the three months average volume of 1,035,312 shares. The stock ended the day 5.59% higher at $57.43. The share price has fallen 31.93% from its 52 week high with a 52 week trading range of 47.75 - 84.37. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $66.08 is below its 200-day moving average of $67.90. Shares of Seattle Genetics have fallen roughly 22.10 percent in the past month and are up 7.35 percent year-to-date.
AccessMER's Seattle Genetics, Inc. Research Report at:
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
MarketEdge has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of MarketEdgeReport.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. MarketEdgeReport.com is neither a registered
For any questions, inquiries, or comments reach out to us directly at:
MarketEdge Report, Unit #901 511 Avenue of the Americas, New York, NY, 10011
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.